775P Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study

Aims: Chemoradiation (CRT) is the standard treatment for locally advanced cervical cancer (LACC). However part of the patients develop recurrence during the first year after treatment despite good visible effect at the first follow-up. The role of completion surgery after radiotherapy (RT) is still debated. A number of papers have showed that up to 60% of patients have residual tumor after CRT and RT. But such a surgery is not widely recommended because of increased morbidity of the treatment. The aim of this study was to assess the results of surgery after radiotherapy of LACC. Method: We retrospectively evaluated data on 86 patients with cervical cancer IB - IIIB stages (mostly stage IIB) who underwent surgery in different modalities after CRT and RT with good clinical response in our department in 2015-2018. Results: When small asymptomatic residual disease was detected early after radiotherapy radical hysterectomy was feasible in most of the cases. Patients with clinical manifestation of recurrence had very poor prognosis. Surgery of recurrent cervical cancer sufficiently deteriorates quality of life, even if possible. Conclusion: Thorough examination with adding MRI imaging after initial treatment of cervical cancer needed to identify patients who may benefit from adjuvant hysterectomy.

Download Full-text

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study

Drug Design Development and Therapy ◽

10.2147/dddt.s214743 ◽

2019 ◽

Vol Volume 13 ◽

pp. 3419-3424 ◽

Cited By ~ 5

Author(s):

Jiangtao Yu ◽

Ziwen Xu ◽

Anyang Li ◽

Jindi Zhang ◽

Yi Wang ◽

...

Keyword(s):

Cervical Cancer ◽

Retrospective Study ◽

Efficacy And Safety ◽

Recurrent Cervical Cancer

Download Full-text

Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-006-0090-x ◽

2006 ◽

Vol 33 (12) ◽

pp. 1399-1407 ◽

Cited By ~ 27

Author(s):

Tzu-Chen Yen ◽

Chyong-Huey Lai ◽

Shih-Ya Ma ◽

Kuan-Gen Huang ◽

Huei-Jean Huang ◽

...

Keyword(s):

Cervical Cancer ◽

Fdg Pet ◽

Recurrent Cervical Cancer ◽

18F Fdg

Download Full-text

Surgical resection of locally recurrent cervical cancer: a single institutional 70 patient series

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200409000-00016 ◽

2004 ◽

Vol 14 (5) ◽

pp. 846-851 ◽

Cited By ~ 3

Author(s):

V. Moutardier ◽

G. Houvenaeghel ◽

M. Martino ◽

B. Lelong ◽

V. J. Bardou ◽

...

Keyword(s):

Cervical Cancer ◽

Local Control ◽

Cancer Recurrence ◽

Palliative Surgery ◽

Morbidity Rate ◽

Actuarial Survival ◽

Recurrent Cervical Cancer ◽

Actuarial Survival Rate ◽

Life Threatening ◽

Threatening Situation

Pelvic recurrence of cervical cancer is a life-threatening situation and only local control can provide hope for remission. The aim of this study was to evaluate the role of surgery in the treatment of cervical cancer recurrence. This retrospective study analyzed a series of 70 patients who underwent resection of cervix locoregional recurrence. Thirteen patients had palliative salvage surgery for pelvic complications. Twenty-nine resections were considered as curative. Fifty recurrences required pelvic exenterations. The hospital mortality rate was 9% and the morbidity rate was 44%. Overall 5-year actuarial survival rate was 23%. Survival was significantly higher: (a) after curative resection and (b) after centropelvic recurrence resection. Local control was obtained in 48% of the cases and 13 patients are alive with a median follow-up of 75 months. In conclusion, the results of this small and heterogen series seem to justify an attempt to resection for centropelvic recurrences whenever possible. Palliative surgery should be reserved to salvage therapy and highly selected patients.

Download Full-text

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2012.08.020 ◽

2012 ◽

Vol 2012 ◽

pp. 122-123

Author(s):

J.T. Thigpen

Keyword(s):

Cervical Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Cervical Cancer

Download Full-text

Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study

Gynecologic Oncology Research and Practice ◽

10.1186/s40661-016-0025-6 ◽

2016 ◽

Vol 3 (1) ◽

Cited By ~ 2

Author(s):

Lindsey E. Minion ◽

Dana M. Chase ◽

John H. Farley ◽

Lyndsay J. Willmott ◽

Bradley J. Monk

Keyword(s):

Cervical Cancer ◽

Feasibility Study ◽

Nano Particle ◽

Recurrent Cervical Cancer ◽

Safety And Efficacy

Download Full-text

Morbidity and mortality of pelvic exenteration for cervical cancer at a German referral center.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e17505 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e17505-e17505

Author(s):

Jelena Boekhoff ◽

Luisa terGlane ◽

Uwe Wagner ◽

Axel Hegele

Keyword(s):

Cervical Cancer ◽

Overall Survival ◽

Pelvic Exenteration ◽

Survival Rates ◽

Operation Time ◽

Previous Treatment ◽

University Hospital ◽

Treatment Modalities ◽

Complication Rates ◽

Recurrent Cervical Cancer

e17505 Background: The purpose of this study was to evaluate data regarding the outcome of pelvic exenteration (PE) when performed for advanced or recurring cervical cancer. Methods: A total of 24 patients underwent PE for cervical cancer at the University Hospital Marburg between 2011 and 2016. Their data were retrospectively assessed and statistically analyzed. Survival was evaluated using the Kaplan-Meyer method. Results: Mean age was 52.2 years (29.7 to 72.6 years), mean BMI was 23.4 kg/m2. Most common indication was squamous cell carcinoma, whereas 3 patients underwent PE for adenocarcinoma. The majority of the tumors (62.5%) were stage pT4. Negative margins could be achieved in 70.8%. Lymph nodes could be assessed in 55% and were tumor-afflicted in 20.8%. 45.8% were treated for recurrent cancer; median recurrence free time between previous treatment and PE was 16 months. Up-front PE was performed in 20.8%. Another 79.2% received treatment prior to PE: 20.8% received all 3 treatment modalities whereas 37.5% had two treatments before (29.2% underwent chemo- and radiotherapy, 8.3% had surgery and radiotherapy) and 20.8% underwent one type of treatment. Anterior PE (APE) and total PE (TPE) were performed in 62.5% and 37.5%, respectively. Median operation time was 324min. Blood products were administered perioperatively in 75%; 37.5% needed 2 or more. Median hospital stay was 25 days. Major complications (Clavien Dindo≥3) were observed in 41.7% and 16.7% had no complications. Overall Survival (OS) was 29.2%; median overall survival was 19.1 months. 2- and 3-year survival rates for curative PE were 50% and 35% respectively. 4 patients underwent PE with palliative intent. Overall survival correlated significantly with R1- (p = 0.012), N1- (p = 0.047) and M1-status p < 0.01), TPE (p = 0.034) and surgical time > 6 h (p = 0.003). Conclusions: In cases of advanced or recurrent cervical cancer gynecologists struggle to find suitable therapeutic options, especially since most patients have already received radio- and/or chemotherapy. PE is a valid option for selected patients that may represent a cure with tolerable complication rates.

Download Full-text